Sethuraman Natarajan 4

What Happened

• Sethuraman Natarajan, President of Research & Development at Entrada Therapeutics, was granted equity awards and had shares sold by the company to cover tax withholdings. On 2026-03-01 the company granted 55,800 shares and an additional 83,200 RSUs (total 139,000 RSUs) at $0.00 (derivative award). To satisfy required tax withholding, the company automatically sold 3,898 shares on 2026-03-02 for a weighted average price of $11.66 (proceeds $45,442) and 7,577 shares on 2026-03-03 for a weighted average price of $11.76 (proceeds $89,078). Total shares sold: 11,475 for aggregate proceeds of ~$134,520.
• These sales were automatic sell-to-cover transactions to satisfy statutory tax obligations (not discretionary sales by the insider).

Key Details

• Transaction dates: RSU grants on 2026-03-01; sell-to-cover on 2026-03-02 and 2026-03-03.
• Sale prices/notes: 3,898 shares at weighted avg $11.66 (range $11.17–$11.91); 7,577 shares at weighted avg $11.76 (range $11.22–$12.095). (Per filing, full per-price breakdown is available on request.)
• Shares acquired: 139,000 RSUs (two entries: 55,800 and 83,200). Shares disposed: 11,475 (sell-to-cover).
• Shares owned after transaction: Not disclosed in this filing.
• Notable footnotes: F1—RSUs vest 25% each year from March 1, 2027–2030; F2—sales were mandatory sell-to-cover; F3/F4—weighted-average sale prices with reported ranges.
• Filing timeliness: Form 4 filed 2026-03-03 covering transactions dated 2026-03-01 through 03-03; filing appears timely per standard Form 4 rules.

Context

• These were RSU awards (derivative grants) with multi-year vesting; RSUs convert to common shares only as they vest. The share sales were automatic sell-to-cover to pay withholding taxes and do not necessarily indicate the insider’s trading intent.